HZNP - Horizon Therapeutics rises in premarket after earnings beat 2022 guidance

Shares of Horizon Therapeutics (NASDAQ:HZNP) are trading 4% higher in the premarket session after its Q4 2021 results beat on the top and bottom lines and it issued 2022 guidance. Net income in the quarter dropped ~9% to $173.2M compared to the prior-year period. Diluted EPS fell to $0.73 from $0.82. Revenue of ~$1B was a ~36% year-over-year increase. The revenue increase was buoyed by a 72% year-over-year increase in its top-selling drug, the thyroid eye disease treatment Tepezza (teprotumumab) to $589.6M. Operating expenses in the quarter of ~$539.9M was a 57% increase from Q4 2020. Horizon (HZNP) ended 2021 with $1.58B in cash. Check out why Seeking Alpha contributor Out of Ignorance considers Horizon (HZNP) a hold.

For further details see:

Horizon Therapeutics rises in premarket after earnings beat, 2022 guidance